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ABSTRACT
Background: Glycogen synthase kinase (GSK)-3β has emerged as an appealing 
therapeutic target for glioblastoma (GBM). Here, we investigated the therapeutic 
effect of the current approved drugs against GBM via inhibition of GSK3β activity 
both, in experimental setting and in a clinical study for recurrent GBM patients by 
repositioning existent drugs in combination with temozolomide (TMZ). 
Materials and Methods: Progression-free and overall survival rates were compared 
between patients with low or high expression of active GSK3β in the primary tumor. 
GBM cells and a mouse model were examined for the effects of GSK3β-inhibitory 
drugs, cimetidine, lithium, olanzapine, and valproate. The safety and efficacy of the 
cocktail of these drugs (CLOVA cocktail) in combination with TMZ were tested in the 
mouse model and in a clinical study for recurrent GBM patients.
Results: Activation of GSK3β in the tumor inversely correlated with patient survival 
as an independent prognostic factor. CLOVA cocktail significantly inhibited cell invasion 
and proliferation. The patients treated with CLOVA cocktail in combination with TMZ 
showed increased survival compared to the control group treated with TMZ alone.
Conclusions: Repositioning of the GSK3β-inhibitory drugs improved the prognosis 
of refractory GBM patients with active GSK3β in tumors. Combination of CLOVA 
cocktail and TMZ is a promising approach for recurrent GBM.
INTRODUCTION
Glioblastoma (GBM), one of the most common 
primary brain tumor in adults, is highly malignant with 
exhibiting aggressive clinical manifestation and a median 
life expectancy of less than 2 years [1]. Biologically, GBM 
is characterized by its high proliferative and invasive 
activity [2]. Only a few drugs were prescribed for GBM: 
temozolomide (TMZ) [3], biodegradable carmustine 
(BCNU) wafer [4, 5], and bevacizumab [6, 7]. Till date, 
no effective therapeutic for GBM has emerged despite the 
development of a variety of molecular-targeted agents 
such as tyrosine kinase inhibitors [8].
Glycogen synthase kinase (GSK)-3β is a 
serine/threonine protein kinase that regulates various 
cellular pathways depending on its substrates by 
phosphorylation [9]. Emerging evidence suggests that 
GSK3β promotes GBM progression by interacting with the 
pivotal molecules that participate in tumor cell survival, 
proliferation, invasion, and resistance to chemoradiation 
therapy [10, 11]. We and others have reported that GSK3β 
inhibition attenuates the proliferation, migration and 
invasion of GBM cells by modulating distinct molecular 
pathways, and sensitizes them to chemotherapeutic agents 
and radiation [12–19]. These studies have substantiated 
GSK3β as therapeutic target of GBM.
Despite experimental evidence supporting the 
therapeutic effect of GSK3β inhibition, none of GSK3β 
inhibitors was approved for treatment of diseases such as 
diabetes mellitus, Alzheimer’s disease, and cancer. The 
development and approval of new drug is a time-consuming 
and expensive process with high rate of failure. Recently, 
drug repositioning to find new applications for existing 
drugs has emerged to overcome this challenge [20]. 
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Drug repositioning attempts to discover new 
therapeutic options for already approved drugs, as their 
pharmacokinetics, pharmacodynamics and post-marketing 
surveillance safety data are readily available [21]. Drugs 
such as cimetidine, lithium carbonate, olanzapine, 
and valproate, prescribed for other diseases inhibited 
GSK3β activity [22–24]. In the present study, these 
GSK3β-inhibiting drugs were examined for therapeutic 
effect against GBM in experimental settings. We also 
explored whether GSK3β activity in clinical tumor tissues 
influences the survival of GBM patients to rationalize 
the targeting of GSK3β. Based on these experimental 
and clinical findings, we conducted a clinical study 
to investigate the safety and therapeutic effect of 
repositioning GSK3β-inhibiting medicines in combination 
with TMZ, in patients with recurrent GBM. 
RESULTS
Activated GSK3β is an unfavorable prognostic 
marker in GBM
First, we investigated the expression of GSK3β and 
pGSK3βY216 (active form) in clinical samples. Interestingly, 
survival analysis of 57 patients with GBM showed a 
significant correlation between pGSK3βY216 expression and 
both progression-free survival (PFS) and overall survival 
(OS) (Figure 1). Subgroup analysis of age, Karnofsky 
Performance Scale (KPS), and O6-methylguanine-DNA-
methyltransferase (MGMT) promoter status, and extent of 
resection (EOR) showed no statistical difference between 
GSK high group and GSK low group (Supplementary 
Table 1). Univariate analysis by Kaplan-Meier method 
showed methylated MGMT promoter, less age, and high 
EOR as predictive factors in our cohort (Supplementary 
Figure 1). Multivariate analysis revealed that activation of 
GSK3β was an independent unfavorable predictive factor 
(Table 1).
Inhibition of GSK3β activity by existing drugs
We examined whether the existent drugs (cimetidine, 
lithium, olanzapine and valproate) inhibit GSK3β activity 
in cells by monitoring the level of pGSS641, the primary 
substrate of GSK3β (reviewed in ref. [9]). The levels of 
pGSS641 in all GBM cells decreased following treatment 
with each drug (Supplementary Figure 2). Hereafter the 
combination of these drugs is referred as “CLOVA cocktail” 
by the initial letters of each drug. While there were some 
differences in the GSK3β-inhibitory effect among the drugs 
and cell lines, the CLOVA cocktail decreased the level of 
pGSS641 in all GBM cells more efficiently than each of 
the cocktail constituents (Figure 2A). The results indicate 
that doses of these four medicines mixed in the CLOVA 
cocktail are within the ranges of clinical use nevertheless 
this cocktail inhibits GSK3β activity in GBM cells.
Effects of the GSK3β-inhibiting drugs on 
invasion and proliferation of GBM cells
The Transwell assay showed that all 4 drugs 
inhibited the invasion of GBM cells to extracellular matrix 
(Supplementary Figure 3A). Lithium showed proliferation-
inhibition at 5 mM and 10 mM in T98 and U87, while only 
at 10 mM in U251 cells. Valproate at 5 mM and 10 mM 
inhibited proliferation of all the 3 cell lines. However, neither 
cimetidine nor olanzapine inhibited cell proliferation at the 
indicated concentrations (Supplementary Figure 3B), and 
this issue was discussed later. 
Next, we investigated the effect of CLOVA cocktail 
that consists of the 4 drugs as a mixture at the lowest 
concentrations (cimetidine, 0.1 mM; lithium, 1 mM; 
olanzapine, 0.1 µM; and valproate, 1 mM) concomitant 
with TMZ on GBM invasion and proliferation. The 
concentrations of cimetidine, lithium, and valproate used in 
culture medium were determined according to their blood 
concentration at the administration of maximum daily 
dose, because the blood-brain barrier (BBB) is damaged in 
GBM tissue. The dose of olanzapine was calculated based 
on its intracerebral concentration at the administration of 
maximum daily dose and its high BBB permeability and 
accumulation in brain tissue [25]. As expected, CLOVA 
cocktail itself showed additive inhibitory effect on cell 
invasion (Figure 2B) while TMZ showed no effect at the 
same time point (data not shown). CLOVA cocktail and 
TMZ inhibited cell proliferation equally, and moreover 
the combination of them showed remarkable inhibitory 
effect on cell proliferation (Figure 2C). The results shown 
in Figure 2, Supplementary Figures 2 and 3 collectively 
suggest a causal association between the effects of CLOVA 
cocktail against the GSK3β activity of GBM cells and their 
proliferative and invasive capacity. 
Effect of CLOVA cocktail on GBM cell invasion 
and proliferation in a brain tumor model
The tumor histology of our animal model 
demonstrated several features, characteristic of human 
GBM, including high proliferative and invasive nature. 
Inhibition of GSK3β activity by treatment with each drug 
and the CLOVA cocktail was confirmed by the decreased 
level of pGSS641 in tumor cells, especially in satellite 
lesions, and the effect of CLOVA cocktail was strongest 
(Figure 3A, Supplementary Figure 4). Similarly, the 
number of diffusely infiltrating tumor cells that stained 
positive for nestin significantly decreased in CLOVA 
cocktail-treated mice (Figure 3A and 3B). Consequently, 
well-demarcated border between the tumor and adjacent 
normal brain tissues was observed both in mice treated 
with each drug alone and the combination (Supplementary 
Figure 4, Figure 3). Previous studies showed that focal 
adhesion kinase (FAK) and Rac1 interact [26] and facilitate 
GBM invasion [27, 28]. The attenuated invasive capacity 
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of GBM tumors following treatment with CLOVA cocktail 
was associated with decrease in activating phosphorylation 
of (pFAKY397 and pFAKY861; Supplementary Figure 5) and 
with alteration in subcellular localization of active Rac1 in 
tumor cells (Figure 3C). These findings are consistent with 
our earlier study showing that GSK3β inhibition decreased 
active Rac1 fraction and FAK phosphorylation in human 
GBM cell lines [29]. 
To compare the tumor proliferative potential, MIB-1 
immunostaining was performed. Interestingly, MIB-
1 staining index remarkably decreased in CLOVA 
cocktail treated-mice (Figure 4A), while less marked 
reduction was observed in mice receiving individual 
drug treatment (Supplementary Figure 4). TMZ alone 
and in combination with the CLOVA cocktail reduced 
the tumor size while the effects were not statistically 
significant (Supplementary Figure 6). Of note, CLOVA 
cocktail significantly prolonged survival of the mouse 
model (Figure 4B).
Phase I/II clinical study 
Seven patients were enrolled in this study 
(Figure 5A). All patients were eligible following 
radiological disease progression (Macdonald criteria [30]) 
and classified as Recursive Partitioning Analysis (RPA) 
class 7 [31]. Median age was 66 years and median KPS 
was 50. MGMT promoter methylation was determined 
in 4 patients (57%). Three patients took CLOVA cocktail 
on the day before death and 4 patients discontinued the 
oral medication because of aspiration pneumonitis, 
2 weeks before death. Median OS after first recurrence 
was 11.2 (95% CI, 3.8–18.6) months in patients treated 
with concomitant CLOVA cocktail with maintenance 
TMZ although they were classified into RPA class 7 
wherein the median survival duration was estimated as 
4.9 months [31], compared to median OS of 4.3 (95% CI, 
2.5–6.1) months in historical control group (log-rank test, 
p = 0.004) (Figure 5B). The concomitant CLOVA cocktail 
with TMZ was safe and well tolerated. Most common 
treatment-related AE was grade 1/2 somnolence caused 
by antipsychotic drug constituents of CLOVA cocktail 
(Table 2). A representative case showed marked reduction 
of the recurrent tumor assessed as partial response (PR) 
9 months after beginning of CLOVA cocktail (Figure 5C). 
Immunohistochemistry using the respective antibodies 
(Supplementary Table 2) of pretreatment and autopsy 
tissue showed decrease in pGSS641, nestin, MIB-1 index 
(pretreatment 32.9% to autopsy 8.0%) and MGMT 
levels (Figure 5D), suggesting that the CLOVA cocktail 
treatment inhibited GSK3β activity, attenuated tumor 
invasion and enhanced TMZ effect, similar to in vivo 
experiment (Figures 3 and 4).
DISCUSSION
In this study, we first demonstrated the independent 
prognostic relevance of tumor-GSK3β activity as 
detected by the increased level of pGSK3βY216 that 
inversely associated with survival of GBM patients, 
while no correlation was found between the expression 
level of mRNA and total protein and the prognosis 
Figure 1: GSK3β activation correlates with poor survival in patients with glioblastoma. (A) immunohistochemical analysis 
of human glioblastoma samples for pGSK3βY216 and total (t) GSK3β. Positive and negative control was a case of metastatic breast carcinoma. 
Scale bar, 50 µm. (B) Kaplan-Meier curves showing survival of glioblastoma patients based on expression level of pGSK3βY216. n, number 
of patients.
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(data not shown). This suggests aberrant GSK3β activity 
in the tumor cells as a new prognostic factor in GBM 
and clinically rationalizes the strategy of targeting of this 
kinase for treatment of GBM. We also found therapeutic 
effects of the existent GSK3β-inhibiting medicines against 
GBM in the experimental and preclinical settings as well as 
a clinical study for the chemotherapy-resistant refractory 
patients. Previously, we and others have reported that 
inhibition of GSK3β activity attenuated proliferation 
and invasion of GBM cells and sensitized them to 
chemotherapeutic agents and radiation by modulating 
distinctive molecular pathways [19, 29]. Consistent with 
our earlier study [29], we confirmed that inactivation of 
GSK3β suppressed the molecular axis involving FAK 
and Rac1 in the present preclinical study. It is notable 
that the cocktail of GSK3β-inhibiting medicines tested in 
this study attenuated survival, migration and invasion of 
GBM cells and animal-model tumors. This cocktail also 
Table 1: Multivariate predictors of survival in our cohort
Variable
Progression-free survival Overall survival
RR 95% CI p* RR 95% CI p*
Low pGSK3βY216 2.15 1.08–4.31 0.030 2.41 1.12–5.25 0.026
Age < 65 1.66 0.81–3.41 0.166 1.90 0.78–4.60 0.155
KPS ≥ 80% 1.49 0.76–2.92 0.247 1.06 0.47 –2.41 0.890
Methylated MGMT promoter 2.30 1.17–4.52 0.015 0.99 0.49–2.01 0.977
EOR ≥ 80% 1.63 0.76–3.51 0.212 1.94 0.79–4.78 0.151
Abbreviations: CI, confidence interval; EOR, extent of resection; GSK3β, glycogen synthase kinase 3β; KPS, Karnofsky 
Performance Scale; MGMT, O6-methylguranine-DNA-methyltransferase; pGSK3βY216, GSK3β phosphorylated at tyrosine 
(Y) 216 residue; RR, relative risk.
*Cox regression model.
Figure 2: Effect of treatment with the CLOVA cocktail on the level of serine 641 phosphorylation of glycogen synthase 
(pGSS641). Expression level of pGSS641 (A), invasion (B) and proliferation (C) in GBM cells. Cells were treated with the CLOVA cocktail (the 
mixture of cimetidine, 0.1 mM; lithium, 1 mM; olanzapine, 0.1 µM; and valproate, 1 mM). A, Western blotting analysis for changes in the 
levels of pGSS641 in GBM cells following treatment with the CLOVA cocktail for 24 hours. The value below the blots shows relative level of 
pGSS641 quantified by densitometry and normalized to that of total (t) GS. All blots were cropped for clarity and conciseness of the images. B, 
Invading cells through a Matrigel-coated Transwell chamber were scored for cells treated with or without CLOVA cocktail for 8 hours. The 
mean number of cells in eight high-power microscopic fields was calculated with standard deviations (SDs). C, Growth analysis of GBM cell 
lines treated with the indicated reagents or without treatment (Control) for 96 h. The plate was read on fluorescence plate reader. B and C: NS, 
not significant; *p < 0.05.
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revitalized TMZ against recurrent GBMs and this effect 
was associated with decreased MGMT expression in the 
patient, thereby resulting in improvement of prognosis 
in patients of GSK high group in spite of low EOR. Our 
present study reinforces the cancer therapeutic effect of 
GSK3β inhibition by repurposing these medicines for 
GBM. It also suggests the necessity for the development 
and approval of specific GSK3β inhibitors to achieve 
efficient therapeutic effect for diseases including cancer.
Combination of multiple drugs with different 
mechanisms of action and/or different binding sites of 
a same target is often required for cancer chemotherapy 
to optimize the therapeutic effects, minimize the adverse 
effects, and prevent the development of treatment 
resistance [32, 33]. CLOVA cocktail showed additive 
effect on GBM proliferation and invasion (Figures 2 and 3; 
Supplementary Figures 3 and 4) but no adverse effect 
in the treated mice. Notably, cell viability showed no 
difference between control group and the group treated 
with CLOVA cocktail at the point of 8 hr when invasion 
assay was evaluated (data not shown). Nowicki et al 
also demonstrated that the effect of GSK3β inhibition on 
migration occurred earlier time points than effects on cell 
viability [34]. There are several ways of inhibiting GSK3β 
activity. They include up-regulation of pGSK3βS9 (inactive 
form), down-regulation of pGSK3βY216 (active form) 
and targeting the catalytic domain and/or the adenosine 
triphosphate (ATP)-binding pocket structure in this 
enzyme (Supplementary Figure 7) [9]. Cimetidine potently 
blocks the catalytic domain of GSK3β. Lithium has dual 
inhibitory effects on GSK3β to induce phosphorylation of 
serine 9 (S9) residue and to compete with Mg2+ that is 
required for GSK3β-dependent substrate phosphorylation. 
Olanzapine also increases the level of S9 phosphorylation 
and docks with the ATP-binding pocket of GSK3β. 
Valproate directly inhibits the activated GSK3β wherein 
Y216 residue is phosphorylated. Aberrant regulation 
of pGSK3βY216 could promote the malignant features of 
GBM [18, 19, 35] since it is an independent prognostic 
factor for GBM patient in the present study. Elevated 
pGSK3βY216 fraction contributed the malignant feature 
of pancreatic cancer [36] and inhibition of pGSK3βY216 
Figure 3: Effect of CLOVA cocktail on the glioblastoma animal model. (A) Representative histological and immunohistochemical 
sections of brain tumors treated with or without CLOVA cocktail. Both activity of GSK3β (estimated by the level of pGSS641) and expression 
of nestin decreased in the satellite lesions. Mice treated with CLOVA cocktail showed a well-demarcated border between the tumor and 
adjacent normal brain tissue. The magnified image of the area in the square is shown in the left upper corner in each panel of pGSS641 and 
nestin. Scale bars, 100 µm. (B) Effects of CLOVA cocktail on the number of pGSS641- and nestin-positive cell clusters. *p < 0.05. (C) 
Immunofluorescence microscopic findings of tumor tissues for active Rac1 (red). Cell nuclei were counterstained with Hoechst 33342 (blue). 
Subcellular localization of active Rac1 changed from cellular rim to whole cytoplasm following treatment with CLOVA cocktail. Magnified 
images of the area in the square are shown in the lower panels. pGSS641, glycogen synthase (GS) phosphorylated at serine 641 residue.
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enhanced the effect of imatinib inducing apoptosis in 
chronic myeloid leukemia [35]. These knowledge and 
observations support the present study showing that 
lithium and valproate inhibiting pGSK3βY216 exhibited 
stronger antitumoral effect than cimetidine and olanzapine 
that induce pGSK3βS9. 
We define or regard the CLOVA cocktail as a 
single drug (the mixture of four constituents) basically 
in this study, and showed its effects against GBM cells 
proliferation and invasion. This effect is consistent with 
a substantial number of previous studies including ours 
showing the tumor-promoting roles of GSK3β, therapeutic 
effect of its inhibition and the underlying biological 
mechanisms in various cancer types including GBM 
[9–16]. The less effect of cimetidine and olanzapine (both 
repurposed, but not specific GSK3β inhibitors) on GBM 
cell proliferation at their limited dose ranges does not 
always make a denial of the solid evidence for the critical 
role of GSK3β in promoting proliferation of tumor cells 
including GBM.
Each of the GSK3β-inhibiting medicines has 
unique cancer therapeutic mechanisms other than its 
GSK3β-inhibitory effect. Cimetidine is a histamine 
H2 receptor antagonist prescribed for gastroduodenal 
ulcers and its anti-tumor activity was reported in many 
cancer types including glioma. It was shown to attenuate 
cell proliferation and migration by blocking histamine 
that promotes tumor angiogenesis [37, 38]. Lithium is 
a classical, non-competent GSK3β inhibitor [23] and 
prescribed for the treatment and prophylaxis of bipolar 
mood disorders and depression [39]. A previous study 
showed a reversible dose-dependent effect of lithium 
on attenuation of glioma cell invasion via inhibition 
of GSK3β activity [34]. Olanzapine is one of the 
most frequently prescribed anti-psychotic agents for 
schizophrenia and bipolar disorder [40]. It has attracted 
Figure 4: Effect of CLOVA cocktail on the glioblastoma animal model.  (A) Immunohistochemistry of MIB-1 and the staining 
index (%) indicating activity of cell proliferation. Scale bars, 100 µm. *p < 0.05. (B) Survival of mice treated with CLOVA cocktail and 
those treated with DMSO/H2O (Control). Log-rank test, p = 0.014. n, number of mice.
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the attention of neuro-oncologists because of its ability 
to enhance the cytotoxic effects of TMZ on GBM [40]. 
GSK3β inhibition by olanzapine stimulated adenosine 
monophosphate (AMP)-activated protein kinase catabolic 
action followed by induction of p53-dependent autophagy, 
which enhances the pro-apoptotic effect of TMZ [41]. 
Valproate is approved for treatment of epileptic seizure, 
bipolar disorder, and migraine. It acts as a histone 
deacetylase inhibitor [42] that alters the chromatin 
structure, consequently increasing DNA accessibility to 
anticancer drugs and enhancing the effect of radiation 
[43, 44], in addition to other anticancer mechanisms [45]. 
In addition to their effects on GSK3β, lithium and 
valproate induced autophagy via inhibition of inositol 
monophosphatase [46] and modulation of oxidative 
stress [47], respectively, resulting in cancer therapeutic 
effect. Anti-tumor effects of valproate were tested by a 
number of clinical trials [48] and some studies showed 
significant survival in GBM patients treated with valproate 
[43, 45, 47]. Recently, a meta-analysis invalidated the use 
of VPA for reasons other than seizure control in patients 
with newly diagnosed GBM outside clinical trials [50], 
suggesting the limitations of single medication with 
GSK3β-inhibitory drug. 
Based on the results of our experimental and 
preclinical studies shown here, we conducted a clinical 
study for the TMZ-resistant recurrent GBM patients 
by repositioning of the GSKβ-inhibiting medicines in 
Figure 5: Phase I/II clinical study.  (A) Treatment protocol in the clinical study. (B) Overall survival of the patients treated with or without 
CLOVA cocktail in combination with temozolomide. (C) MRI images of a representative case (Case No. 6 in Table 2) of 77 y.o. male with 
recurrent GBM of the left parietal lobe. Three (3M), six (6M), and nine months (9M) after beginning of CLOVA cocktail (0M), the recurrent 
tumor adjacent to the resection cavity shrank continuously. All MRI images were post-contrast axial T1-weighted. (D) Immunohistochemical 
findings of the recurrent tumor before the treatment and the tumor obtained by autopsy in the case shown in C. Scale bar 50 µm; GS, glycogen 
synthase; pGSS641, GS phosphorylated at serine 641 residue; MGMT, O6-methylguanine-DNA methyltransferase; RTx, radiotherapy; TMZ, 
temozolomide.
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combination with TMZ (UMIN:00005111). Patients 
treated with this regimen showed significant longer 
survival (median survival 11.2 months after recurrence) 
than historical control (median survival 4.4 months) 
treated with TMZ alone even though all the former 
patients were classified as RPA 7 in which the bad 
prognosis is predicted [31]. Immunohistochemical analysis 
of the patients’ tumors (Figure 4) suggested that the 
repurposed drugs inhibited GSK3β activity in the tumor 
cells, decreased expression of MIB-1 cell proliferation 
marker, and reduced invasion by the residual tumor 
cells. Although this clinical study has limitations such as 
single institution and small number of patients enrolled, 
it was first to provide the evidence of GSK3β-targeted 
cancer therapy based on drug repositioning. Not all, but 
combination of some GSK3β-inhibiting medicines might 
be enough for inhibition of aberrant GSK3β in the tumors. 
The next step toward clinical translation of this therapeutic 
strategy is to plan a large-scale, prospective multicenter 
trial to establish the optimum combination of the GSK3β-
inhibiting medicines. A subsequent trial is also important 
to compare the effects of them in combination with TMZ 
and with bevacizumab. It will clarify whether the GSK3β-
targeted therapy can prevent the GBM invasion enhanced 
in the bevacizumab-resistant tumors [51, 52].
Accumulating evidence has shown that inhibition of 
GSK3β provides dual benefits for the treatment of GBM 
patients by attenuation of tumor progression [17, 29] and 
protection from neurodegenerative effects of irradiation 
[53, 54]. This study also supports and promotes future 
clinical translation of the GSK3β-targeted therapy by drug 
repositioning. To ascertain the effect of GSK3β-targeted 
therapy with repurposing drugs, large multicenter clinical 
trial is currently in progress to validate the efficacy and 
safety of CLOVA cocktail in combination with TMZ, and 
best combination of the drugs composed of the cocktail in 
patients with recurrent GBM. 
MATERIALS AND METHODS
Established predictive factors and GSK3β 
activity in the tumor of GBM patients
We examined 57 patients with GBM (Supplementary 
Table 1) for influence of tumor-GSK3β activity on 
their survival. This study was approved by Kanazawa 
University Medical Ethics Committee. Fresh tumor tissues 
were obtained by biopsy and surgery and the remaining 
tissue samples were fixed in 4% paraformaldehyde 
and embedded in paraffin for routine histopathologic 
examination and immunohistochemical analysis. The 
histological diagnosis was determined according to the 
revised World Health Organization criteria [55]. 
Established predictive factors including age [56], 
Karnofsky Performance Status (KPS) [56], EOR [57], and 
methylation in O6-methylguanine-DNA methyltransferase 
(MGMT) gene promoter [58] were analyzed in these patients. 
Progression-free survival (PFS) and overall survival (OS) 
were calculated from the initial operation to last magnetic 
resonance imaging (MRI) and to death, respectively. Log-
rank test for univariate analysis was performed to determine 
statistical significance of Kaplan-Meier survival curve. Cox 
proportional hazard regression model was used to identify 
the multivariate predictors of survival. 
Table 2: Patient characteristic enrolled and the results of the clinical study
Case Age Sex KPS MGMT* Response† RPA class OS after first recurrence (week) AEs¶
1 70 Male 20 M PR 7 73.1 2
2 66 Male 50 U SD 7 28.6 1
3 64 Female 30 M SD 7 28.4 1
4 75 Male 40 U SD 7 93.1 1
5 55 Male 50 U SD 7 33.0 1
6 77 Male 50 M SD 7 46.7 2
7 60 Female 50 M SD 7 44.9 1






















Abbreviations: AE, adverse event; KPS, Karnofsky Performance Status; MGMT, O6-methylguanine-DNA-methyltransferase; PD, progressive disease; PFS, 
progression-free survival; PR, partial response; OS, overall survival; RPA, recursive partitioning analysis; SD, stable disease. 
*MGMT promoter status; ND, not detectable; M, methylated; U, unmethylated.
†Response was assessed according to Macdonald criteria.
¶AE score was based on Common Terminology Criteria for Adverse Events (CTCAE) version 4.0. 
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Methylation of MGMT promoter was examined by 
methylation-specific PCR. Genomic DNA was extracted 
from paraffin sections of tumor by using QIAamp DNA 
FFPE Tissue kit™ (QIAGEN, Hilden, Germany). Sodium 
bisulfite conversion of 1 µg DNA was performed using 
an EpiTect Bisulfite Kit (QIAGEN) according to the 
manufacture’s protocol. Methylation-specific PCR of 
bisulfite-converted DNA was carried out by a nested, 
two-stage PCR approach as described previously [59] 
using GeneAmp PCR System 2700 (Applied Biosystems, 
Foster city, CA, USA). U87 and U138 cell lines were used 
as methylated and unmethylated controls, respectively. 
Amplified PCR products were separated by 3% agarose 
gel electrophoresis and visualized with ethidium bromide.
Tumor GSK3β activity was examined 
immunohistochemically for the level of phosphorylation 
at tyrosine (Y) 216 residue (pGSK3βY216). Representative 
paraffin sections of the tumors were immunostained with 
GSK3β and pGSK3βY216 antibodies (BD Biosciences, 
San Jose, CA, USA) (Supplementary Table 2), using 
Envision+ Kit (DAKO Japan, Kyoto, Japan) as described 
previously [60]. Images were acquired with a BZ-X700 
microscope (Keyence, Osaka, Japan) and digitally 
processed with the Keyence Analysis Software. The 
patients were classified into 2 groups depending on the 
level of pGSK3βY216 as “GSK high” (≥ 50% of the tumor 
cells were labeled) and “GSK low” (< 50% of the tumor 
cells were labeled). Immunohistochemical evaluation was 
carried out by neuropathologist (H.S.) and oncologist 
(T.M.) in independent readings. 
Cell culture
Human glioma cell lines T98, U87, U251, and U138 
were obtained from American Type Culture Collection 
(ATCC) in 2009. These cell lines were characterized 
in the resource institute by short tandem repeat profile 
analysis. Authentication of the cell lines was unnecessary 
because cells were expanded by culturing them for less 
than two passages and stored at −80°C. Low-passage cells 
were used for experiments within the period of 6 months 
after resuscitation. They were maintained in Dulbecco’s 
modified Eagle medium (DMEM) supplemented with 10% 
fetal bovine serum (FBS) at 37°C with 5% CO2. All cells 
were Mycoplasma free. 
Existent GSK3β-inhibiting medicines and 
temozolomide
Six GSK3β-inhibitory drugs were reported; 
lithium [61, 62], cimetidine [63], gemifloxacin [63], 
hydroxychloroquine [63], olanzapine [64], and valproate 
[24, 65]. Of these, 4 drugs were selected because of their 
general usage for the symptoms of the patients suffering from 
brain tumor; cimetidine for gastroduodenal ulcer, lithium and 
olanzapine for mood disorder, and valproate for seizure. 
imetidine, lithium, olanzapine and valproate were 
purchased from WAKO Pure Chemicals (Osaka, Japan). 
For stock solutions, cimetidine and olanzapine were 
dissolved in dimethyl sulfoxide (DMSO), and lithium and 
valproate were dissolved in distilled water. As described 
in the Results, the concentrations of these drugs used in 
culture medium were as follows: cimetidine: 0.1, 0.5, and 
1 mM; lithium: 1, 5, and 10 mM; olanzapine: 0.1, 0.5, and 
1.0 μM; and valproate: 1, 5, and 10 mM. The combination 
of these drugs at their lowest concentration was referred as 
“CLOVA cocktail” by taking the initial letters of each drug. 
Temozolomide (TMZ) was purchased from Sigma-
Aldrich (St Louis, MO, USA). The concentration of this 
agent was 200 µM for cell culture and 100 mg/kg for 
animal model experiment. 
Western blot analysis
Cellular protein was extracted from cultured 
cells following the treatment using lysis buffer (Sigma-
Aldrich) containing a mixture of protease and phosphatase 
inhibitors (Sigma-Aldrich). A 15-μg aliquot of whole 
protein extract was analyzed by Western immunoblot 
for the protein of interest (Supplementary Table 2), as 
described previously [66]. β-actin was used as loading 
control. Immunoblot signals were measured using the CS 
analyzer (version 2.0; ATTO, Tokyo, Japan).
Cell invasion assay
Cell invasion assays were performed using modified 
Boyden chambers consisting of Transwell with pre-coated 
Matrigel membrane filter inserts in 24-well tissue culture 
plates (BD Biosciences) as described previously [66]. 
Serum-deprived cells suspended in DMEM containing 0.1% 
fetal bovine serum (FBS) were added to each Transwell. 
After incubation at 37°C for 8 h, non-invading cells were 
removed by wiping the upper side of the membrane, and the 
invading cells were fixed with methanol and stained with 
Diff-Quick Kit (Sysmex, Kobe, Japan). The invading cells 
on the filter were counted from 8 randomly selected high-
power microscopic fields. The mean number of cells and 
standard deviations were calculated. 
Cell proliferation assay
Alamar Blue assay (Biosource, Camarillo, CA, 
USA) was performed according to manufacturer’s manual. 
Practically, 1,000 cells of each population were seeded in 
wells of 96-well plastic plates in 200 μl of culture medium 
supplemented with 0.1% FBS. The plates were incubated 
for 4 h at 37°C, and 20 μl Alamar Blue (10% of total 
volume) was added to the cells and incubated. The plate 
was read on a fluorescence plate reader (excitation, 30 nm; 
emission, 590 nm) at 0, 24, 48, 72, and 96 h. Averages of 
the fluorescence values were calculated and plotted. To 
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investigate the influence of drugs on cell proliferation, 
cells were serum starved for 24 h and seeded in the 
proliferation assay format. The cells were then treated with 
various concentrations of each drug, CLOVA cocktail, 
TMZ, or with the latter two in combination. 
Mouse model of GBM and treatment
Following an institutional review board-approved 
protocol, we generated a mouse brain tumor model 
of human GBM by retrovirus-mediated introduction 
of the mutant K-ras gene (K-rasG12V) in neurospheres 
derived from the brain of p16Ink4A−/−/p19Arf−/− mouse and 
transplantation of them into the brain of wild-type mice 
according to our previous study [67]. The activation of 
GSK3β was validated both in the cultured sphere and the 
in vivo developed tumor by Western blot (data not shown). 
These mice were treated with the CLOVA cocktail or TMZ 
either alone or in combination. Practically, the 20 mice 
were randomly assigned to four groups for treatment with 
H2O/DMSO as control (n = 5), CLOVA cocktail alone 
(n = 5), TMZ alone (n = 5), and CLOVA cocktail and TMZ 
in combination (n = 5). Each drug of CLOVA cocktail at 
dose equivalent to the human dose was normalized to 
mice weights as follows; cimetidine 13.3 mg/kg; lithium 
6.7 mg/kg; olanzapine 167 μg/kg; and valproate 13.3 mg/kg. 
CLOVA cocktail was orally administered every day and 
TMZ was administered intraperitoneally at 100 mg/kg 
for first 5 days. Following 2 weeks of treatment, all 20 
mice were euthanized. For survival study, the 10 mice 
were treated with H2O/DMSO (n = 5) or CLOVA cocktail 
(n = 5). All animal experiments followed the Guidelines 
for the Care and Use of Laboratory Animals at Kanazawa 
University that covers the national guideline. 
Representative paraffin sections of the tumors were 
immunostained for glycogen synthase phosphorylated 
at S641 residue (pGSS641), MIB-1, nestin, and focal 
adhesion kinase phosphorylated at Y397 and Y861 
residue (pFAKY397 and pFAKY861) using the respective 
antibodies (Supplementary Table 2) as described above. 
Nestin-positive tumor cell clusters were scored to evaluate 
the degree of invasion as described previously [68]. 
Representative paraffin sections of the tumors were 
immunostained with a 1:50 dilution of anti-active Rac1 
monoclonal antibody (NewEast Biosciences, King of 
Prussia, PA, USA) and then incubated in biotinylated 
horse anti-mouse IgG antibody (1:50; Vector Laboratories, 
Burlingame, CA, USA), followed by incubation with 
Alexa Fluor 594-labelled streptavidin (1:500; Vector 
Laboratories). Non-immune mouse serum at 1:50 dilution 
was used as negative control in immunostaining. The 
stained sections were mounted with the mounting medium 
for fluorescence with 4′,6′-diamidino-2-phenylindole 
(DAPI; Santa Cruz Biotechnology, Heidelberg, Germany). 
Images were captured with a BZ-X700 microscope 
(Keyence).
Design of clinical study
The single center, single-arm, clinical study 
investigated the efficacy and safety of CLOVA cocktail 
in combination with TMZ in patients with recurrent 
GBM in Kanazawa University Hospital from January 
2009 to October 2010 under approval by Medical Ethics 
Committee of Kanazawa University (UMIN Clinical Trial 
Registry: UMIN000005111). Written informed consent 
was obtained from all patients. Primary endpoint was 
OS after first recurrence. Secondary endpoint was safety 
compared with matched historical control population 
treated with TMZ alone. 
Patients
Adult patients (age ≥ 18 years) with histologically 
proven recurrent GBM after standard chemoradiation 
therapy with TMZ were eligible for the study (Table 2). 
Treatment
CLOVA cocktail comprising 800 mg cimetidine, 400 mg 
lithium, 10 mg olanzapine, and 800 mg valproate was orally 
administered daily. Dose of each drug was determined based 
on medical package insert, and therapeutic drug monitoring 
of lithium and valproate was performed every month. 
Maintenance TMZ at 200 mg/m2/day was administered for 5 
consecutive days every 4 weeks (Figure 5A). 
Efficacy and safety assessments
A baseline gadolinium-enhanced MRI scan was 
performed within 1 week before beginning the treatment. 
MRI was repeated every 1 month. Progression was based 
on investigators’ clinical and radiological assessment 
according to Macdonald criteria [30]. Safety was evaluated 
by descriptively summarizing adverse events (AEs), 
laboratory assessments, and physical examinations. All 
AEs were recorded according to Common Terminology 
Criteria for Adverse Events (CTCAE) version 4.0. 
Matched historical controls
Matched historical controls were identified from 
records of patients with recurrent GBM who had received 
treatment with maintenance TMZ at 200 mg/m2/day in 
Kanazawa University Hospital (Supplementary Table 3) 
same as the patients enrolled the study. 
Statistical analyses
Statistical significance was determined using 
Student’s t-test, Mann-Whitney U test and Fisher’s exact 
test for comparison of two groups as appropriate. Log-rank 
analysis was used to determine statistical significance of 
Kaplan-Meier survival curve. All analyses were performed 
using SPSS statistical package version 19 for Macintosh 
(IBM Japan Ltd., Tokyo, Japan). The significance level 
was set at p = 0.05.
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